#United States #Denver #Kazmira Therapeutics #1Cannabis #CBD Education

Introduction

Kazmira Therapeutics, a Colorado-based company, has launched 1Cannabis, an innovative online education platform aimed at both clinicians and patients interested in medical cannabis. This platform marks a significant advancement in the healthcare landscape, addressing the growing demand for knowledge about cannabinoid therapies, particularly cannabidiol (CBD).

The Need for Education

As the medical cannabis sector continues to evolve, clinicians often find themselves grappling with limited knowledge and resources when it comes to prescribing cannabinoid products. According to co-founder and co-CEO Pulak Sharma, the existing education gap for healthcare providers has been a critical barrier in ensuring that patients receive the best possible care. "Licensed providers and compounding pharmacies have not kept pace with the accelerating demand for cannabinoid therapies," Sharma said. In contrast, patients are increasingly seeking alternatives that provide better safety profiles compared to traditional medications such as opioids.

Overview of 1Cannabis

The 1Cannabis platform features three comprehensive programs specifically designed for clinicians and patients:
1. CBD001: Cannabinoid Basics - A 30-minute program tailored for patients that outlines essential facts about CBD.
2. CBD101: Core Cannabinoid Fundamentals - A thorough 90-minute program for healthcare providers focusing on the endocannabinoid system, safety measures, and potential drug interactions.
3. CBD201: Clinical Protocols - This program provides clinical considerations and protocols for specific patient populations, helping bridge the gap between theoretical knowledge and practical application.

This structured approach enables clinicians to engage in evidence-based conversations with their patients, fostering a more cohesive understanding of how medical cannabis differs from retail CBD products.

Enhancing Provider Confidence

Dr. Rachit Marwaha, a board-certified physician and medical advisor to Kazmira, emphasized the importance of informed discussions between providers and patients. He referred to a recent JAMA report indicating that merely 5% of patients using cannabis for health reasons had documented their usage in medical records. This lack of documentation poses risks for potential drug interactions and overlaps in treatment plans. "Equipping physicians with the right information is paramount for comprehensive healthcare delivery," Dr. Marwaha explained.

The Role of Regulatory Alignment

Recently, the Centers for Medicare & Medicaid Services (CMS) introduced a pilot initiative aimed at enabling easier access to certain CBD medical products. In this changing regulatory landscape, 1Cannabis has developed clinical and operational protocols that align with these emerging pathways. These protocols include

• - Patient intake processes,
• - Physician-guided dosing strategies,
• - Detailed documentation workflows,
• - Longitudinal patient monitoring.

Accessibility and Future Directions

The 1Cannabis platform is committed to making education widely available; both the CBD001 and CBD101 programs are complimentary for all clinicians and patients across the United States. Meanwhile, the CBD201 program is in development and will be offered for purchase soon.

Furthermore, this initiative builds upon the recent launch of the Kazmira Pharmacy, which is recognized as the first regulated pharmacy in the nation providing prescription CBD to patients in Colorado. This vertically integrated approach positions Kazmira Therapeutics as a leading player in the prescribed cannabinoid healthcare sector.

Conclusion

In summary, 1Cannabis represents a much-needed advancement in the realm of medical cannabis education, addressing the knowledge gap that has historically hindered effective patient care. As more clinicians become educated about cannabinoid therapies, patients will benefit from better-informed treatment options, leading to improved healthcare outcomes across the board. Kazmira Therapeutics is not only transforming the way healthcare providers interact with medicinal cannabis but is also setting a new standard of care that other companies may choose to follow in this dynamic field.